NeOnc raises $1M from Saad Naja; AI study shows ultrasound boosts NEO100 against brain tumors

NEONC TECHNOLOGIES HOLDINGS, INC.

Issued 111,732 shares at $8.95 to Saad Naja, raising gross proceeds of ~$1M for working capital.
Preclinical collaboration with USC (bioRxiv) shows NEO100 combined with focused ultrasound enhances tumor killing in glioblastoma, medulloblastoma, meningioma, and metastases.
AI-trained platform using 200+ molecular descriptors identified NEO100 as a leading sonosensitizer; 3D-bioprinted organoids validated results in days vs. weeks.
Results support moving NEO100-plus-ultrasound into future clinical trials for multiple primary and metastatic brain tumors.
CEO Heshmatpour says findings expand NEO100's commercial and clinical opportunity beyond current indications.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.